Sanofi Cancer Drug Setback Hobbles Potential Blockbuster
- Drugmaker’s shares slump on amcenestrant’s disappointment
- Treatment didn’t help patients live longer without disease
This article is for subscribers only.
Sanofi’s experimental medicine amcenestrant failed in a clinical test for breast cancer, dealing a blow to one of the French drugmaker’s potential blockbusters.
The patients who got the drug, rather than endocrine treatment, didn’t live longer without the disease progressing -- a key benefit measure known as progression-free survival -- in the phase 2 trial, Sanofi said Monday. The stock fell as much as 6.2% in Paris trading, the steepest drop in almost two years.